Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Issue of LTIP Awards

22nd Dec 2020 15:29

RNS Number : 5810J
Diurnal Group PLC
22 December 2020
 

22 December 2020

 

Diurnal Group plc

("Diurnal" or the "Company")

 

Issue of Long-Term Incentive Plan awards

 

On 22 December 2020, Diurnal issued a total of 2,235,383 par value options over ordinary shares of 5 pence in the Company under the Diurnal Group plc Long Term Incentive Plan (the "Plan"), of which the following were issued to persons discharging managerial responsibilities ("PDMR"):

 

PDMR

Total number of shares awarded

Type of awards

Martin Whitaker

514,705

Performance share award

Richard Bungay

411,764

Performance share award

Richard Ross

137,860

Performance share award

 

The performance share awards will ordinarily vest no earlier than the third anniversary of their grant subject to the grantee's continued service and to the extent to which the performance conditions set for the awards are satisfied. Such awards may potentially vest until the fifth anniversary of their grant date. Performance conditions are as follows:

· Achieving a target share price of 100 pence for a three-month rolling period during the five years following grant

· Confirmation from the US FDA of progression of DITEST™ to Phase 3 development

· Global Alkindi® and Chronocort® sales for the year ended 30 June 2023 in line with Company forecasts

· Submission of Marketing Authorisation Application in Japan for Alkindi® or a Japanese partner in place

· Chronocort® approved in adrenal insufficiency (AI) in at least one major global territory

 

The awards were granted under award agreements that incorporated the terms of the Plan. No consideration is due to be payable on vesting.

 

Details of the full notifications received by the Company are set out below:

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 Martin Whitaker

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Executive Officer

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Diurnal Group plc

b)

 

LEI

 

213800I2HNUNZN1LDH29

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Grant of award of options under the Diurnal Group plc Long Term Incentive Plan over Ordinary shares of 5p each

Identification code

Ordinary shares: GB00BDB6Q760

b)

 

Nature of the transaction

 

Grant of awards under the Diurnal Group plc Long Term Incentive Plan as par value options as follows:

 

Performance share award over 514,705 ordinary shares.

 

The performance share award will ordinarily vest no earlier than the third anniversary of its grant subject to continued service and to the extent to which the performance conditions set for the awards are satisfied. Such award may potentially vest until the fifth anniversary of its grant date.

 

No consideration is due to be payable on vesting.

c)

 

Price(s) and volume(s)

Price(s)

Volume(s)

Nil exercise price

514,705

d)

 

Aggregated information

- Aggregated volume

Award over 514,705 ordinary shares.

- Price

Nil price payable for grant and upon exercise

e)

 

Date of the transaction

 

22 December 2020

f)

 

Place of the transaction

 

Outside a trading venue

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 Richard Bungay

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Financial Officer

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Diurnal Group plc

b)

 

LEI

 

213800I2HNUNZN1LDH29

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Grant of award of options under the Diurnal Group plc Long Term Incentive Plan over Ordinary shares of 5p each

Identification code

Ordinary shares: GB00BDB6Q760

b)

 

Nature of the transaction

 

Grant of awards under the Diurnal Group plc Long Term Incentive Plan as par value options as follows:

 

Performance share award over 411,764 ordinary shares.

 

The performance share award will ordinarily vest no earlier than the third anniversary of its grant subject to continued service and to the extent to which the performance conditions set for the awards are satisfied. Such award may potentially vest until the fifth anniversary of its grant date.

 

No consideration is due to be payable on vesting.

c)

 

Price(s) and volume(s)

Price(s)

Volume(s)

Nil exercise price

411,764

d)

 

Aggregated information

- Aggregated volume

Award over 411,764 ordinary shares.

- Price

Nil price payable for grant and upon exercise

e)

 

Date of the transaction

 

22 December 2020

f)

 

Place of the transaction

 

Outside a trading venue

 

 

Details of the person discharging managerial responsibilities / person closely associated

 

Name

 

 Richard Ross

Reason for the notification

 

Position/status

 

Chief Scientific Officer

Initial notification /Amendment

 

Initial notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

Name

 

Diurnal Group plc

LEI

 

213800I2HNUNZN1LDH29

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

Description of the financial instrument, type of instrument

Grant of award of options under the Diurnal Group plc Long Term Incentive Plan over Ordinary shares of 5p each

Identification code

Ordinary shares: GB00BDB6Q760

Nature of the transaction

 

Grant of awards under the Diurnal Group plc Long Term Incentive Plan as par value options as follows:

 

Performance share award over 137,860 ordinary shares.

 

The performance share award will ordinarily vest no earlier than the third anniversary of its grant subject to continued service and to the extent to which the performance conditions set for the awards are satisfied. Such award may potentially vest until the fifth anniversary of its grant date.

 

No consideration is due to be payable on vesting.

Price(s) and volume(s)

Price(s)

Volume(s)

Nil exercise price

137,860

Aggregated information

- Aggregated volume

Award over 137,860 ordinary shares.

- Price

Nil price payable for grant and upon exercise

Date of the transaction

 

22 December 2020

Place of the transaction

 

Outside a trading venue

 

 

For further information, please visit www.diurnal.co.uk or contact:

Diurnal Group plc

+44 (0)20 3727 1000

Martin Whitaker, Chief Executive Officer

Richard Bungay, Chief Financial Officer

Panmure Gordon (UK) Limited (Nominated Adviser and Sole Broker)

+44 (0)20 7886 2500

Corporate Finance: Freddy Crossley, Emma Earl

Corporate Broking: Rupert Dearden

FTI Consulting (Media and Investor Relations)

+44 (0)20 3727 1000

Simon Conway

Victoria Foster Mitchell

 

 

 

Notes to Editors

 

 

About Diurnal Group plc

 

Founded in 2004, Diurnal is a UK-headquartered, European specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency and hypogonadism. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

 

For further information about Diurnal, please visit www.diurnal.co.uk

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHZZMZZKZNGGZM

Related Shares:

DNL.L
FTSE 100 Latest
Value8,809.74
Change53.53